Aims: Allergic rhinitis is a very frequent inflammatory disease of nasal mucosa that warranties its symptomatic treatment.

Objective: To evaluate the therapeutic effect of the mequitazine in the treatment of patient with allergic rhinitis and conjunctivitis symptoms, the grade of the physician and patient satisfaction, as well as the quality of life and the side effects of the treatment.

Patients And Method: Clinical multicentric, open, longitudinal study made in the Mexican Republic with patients from 3 to 18 years of age and 113 doctors. All the patients were carried out a clinical evaluation, registration of the intensity of the symptoms and signs and the affectation in their daily activities. The diagnosis of allergic rhinitis and conjunctivitis settled down with base on the data of the clinical history and the exploration. All the patients were prescribed mequitazine. To those of 3 to 5 years of age: 7.5 mL a day, to those of 6 to 12 years: 10 mL, and to those of 12 to 18 years a pill of 10 mg a day.

Results: 374 patients were studied: 44.5% of the female sex. The age limits with more number of patients were from 3.5 to 11 years. The percentage of patients in a moderate or severe state at the beginning of the study was of 74%. To the first revision they went down to 22%. In second 16%, at third the moderate form represented 8% and the severe form disappeared. The doctor qualified the results of excellent to very good in 88% of the cases and the patient or his relatives in 85%.

Download full-text PDF

Source

Publication Analysis

Top Keywords

allergic rhinitis
16
rhinitis conjunctivitis
8
patients years
8
years age
8
patients
6
years
5
[symptomatic treatment
4
allergic
4
treatment allergic
4
rhinitis
4

Similar Publications

Objective: The symptom burden associated with allergic rhinitis (AR) negatively impacts the life of people living with the condition. Although the impact of AR on educational outcomes and the effect of AR-relieving medication have been investigated, the availability of up-to-date, population-based, real-world evidence is limited. Therefore, the aim was to investigate the impact of AR and AR-relieving medication on educational outcomes.

View Article and Find Full Text PDF

Background: Allergic rhinitis (AR) is a common chronic respiratory disease that can lead to the development of various other conditions. Although genetic risk loci associated with AR have been reported, the connections between these loci and AR comorbidities or other diseases remain unclear.

Methods: This study conducted a phenome-wide association study (PheWAS) using known AR risk loci to explore the impact of known AR risk variants on a broad spectrum of phenotypes.

View Article and Find Full Text PDF

Insights into structural and binding studies of pollen allergen Bet v 1 using computational approaches.

In Silico Pharmacol

January 2025

Bioinformatics Infrastructure Facility, Sri Venkateswara College (University of Delhi), Benito Juarez Road, Dhaula Kuan, New Delhi, 110021 India.

Unlabelled: Bet v 1, the European White Birch tree pollen allergen is responsible for a number of allergic responses in humans such as rhinitis, asthma and oral allergy syndrome. The allergen belongs to pathogenesis-related (PR) class 10 protein superfamily and exists in several naturally occurring isoforms. Limited structural information on Bet v 1 isoallergens and variants prompted us to carry out their in silico structural characterization.

View Article and Find Full Text PDF

Objective: This cross-sectional study aimed to evaluate parents' knowledge, attitudes and practices (KAP) concerning the prevention and treatment of dust mite allergy in children.

Design: This cross-sectional study survey was conducted from September to December 2022 at Shengjing Hospital, Affiliated with China Medical University.

Participants: A total of 503 parents of children with dust mite allergies participated, with 253 parents having children undergoing desensitisation treatment and 250 parents whose children did not.

View Article and Find Full Text PDF

Serum Periostin as a Potential Biomarker in the Evaluation of Allergic Rhinitis: A Pilot Study.

J Asthma Allergy

January 2025

Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.

Purpose: Although periostin has recently emerged as a new mediator in chronic allergic diseases, particularly in upper airway disease, its significance as a biomarker for allergic rhinitis (AR) is still unclear. Therefore, we aimed to assess the potential of periostin as a novel candidate biomarker for diagnosing and assessing the severity of AR.

Patients And Methods: A total of 40 patients with AR and 22 healthy controls, all aged over 18 years, were recruited for the study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!